NOW APPROVED

HEAD TO HOPE

MODEYSO is the first and only treatment for adults and children 1 year of age and older with a certain type of brain tumor called diffuse midline glioma that has a specific “H3 K27M” gene mutation and has gotten worse after other treatments.

MODEYSO is the first and only treatment for adults and children 1 year of age and older with a certain type of brain tumor called diffuse midline glioma that has a specific “H3 K27M” gene mutation and has gotten worse after other treatments.

H3 K27M mutation

The H3 K27M mutation is associated with the development of rare brain tumors known as diffuse midline gliomas.

Discover more

A targeted treatment

The effects of MODEYSO were evaluated in an analysis of 50 patients with H3 K27M–mutant diffuse midline glioma.

See the data

Once-weekly dosing

MODEYSO is taken orally, once a week on an empty stomach, so it can fit into your routine.

Get the details

Image
ChimerixCares™ program Logo

Support is available

ChimerixCares™ is here to help you or someone you care for along the path of treatment with MODEYSO.

Learn more